Jan 29 (Reuters) - Medical device maker ResMed (RMD.N), opens new tab on Thursday beat Wall Street estimates for second-quarter profit on the back of strong demand for its devices used to manage sleep ...

Resmed (NYSE: RMD) + announced today that it received FDA clearance for its Smart Comfort personalized therapy offering. San Diego–based Resmed calls Smart Comfort (which was submitted to the FDA as ...

Sleep apnea device maker ResMed will expand its American manufacturing operations and open a new facility in Indianapolis in 2027 but says it is not due to pressure from President Donald Trump for ...

Fractus, a company specializing in geometry-based antenna technology and IP licensing, has filed a patent infringement suit against respiratory leader ResMed. The complaint was filed in the United ...

ResMed, an ASX healthcare leader, is well-positioned to capitalise on the growing demand for sleep apnoea treatment and digital health solutions, offering potential long-term rewards. The company's ...

Git isn’t hard to learn. Moreover, with a Git GUI such as Atlassian’s Sourcetree, and a SaaS code repository such as Bitbucket, mastery of the industry’s most powerful version control tools is within ...

Resmed has beaten full-year earnings and revenue forecasts on the back of strong global sales of its devices to treat sleep apnoea, shrugging off the threat of US President Donald Trump’s trade ...

Revenue: $1.35 billion, a 10% increase year-over-year. Gross Margin: 61.4%, an expansion of 230 basis points year-over-year. Free Cash Flow: $1.7 billion for fiscal year 2025. Net Income: Increased by ...

Resmed announced that it will release its financial and operational results for the fourth quarter of fiscal year 2025 on July 31, 2025, after the market closes. Following the release, management will ...

ResMed dominates an enormous, underdiagnosed market with recurring revenue and digital health leadership, yet trades below its historical earnings multiples, offering compelling value. The company’s ...